CN102356837B - Combined food for reducing blood sugar - Google Patents
Combined food for reducing blood sugar Download PDFInfo
- Publication number
- CN102356837B CN102356837B CN2011102844487A CN201110284448A CN102356837B CN 102356837 B CN102356837 B CN 102356837B CN 2011102844487 A CN2011102844487 A CN 2011102844487A CN 201110284448 A CN201110284448 A CN 201110284448A CN 102356837 B CN102356837 B CN 102356837B
- Authority
- CN
- China
- Prior art keywords
- powder
- blood sugar
- astragaloside
- food
- grifolan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a combined food for reducing blood sugar. The food is formed by maitake polysaccharide powder and total saponins powder of astragalus which are mixed according to the mass ratio of 1:2 to 2:1; the maitake polysaccharide powder is extracted from maitake fruit bodies, wherein the content of maitake polysaccharide is more than 50%; the total saponins powder of astragalus is extracted from astragalus, wherein the content of total saponins powder of astragalus is more than 50%. The combined food has the functions of reducing fasting blood glucose of a 2-type diabetes KKay mouse model and a nutritional type 2-type diabetes mouse model, enhancing the physiological activity in a synergetic manner, and better improving the respective function of reducing the blood sugar; and the toxicological tests show that the application of the combined food is safe. The combined food can be used for preparing a health-care food and medicaments for reducing the blood sugar in an auxiliary manner, can reduce the fasting blood glucose and improve the clinical symptoms caused by high blood sugar.
Description
Technical field
The invention belongs to health food, biomedicine field, be specifically related to be used for assistant hypoglycemia healthcare food, be i.e. a kind of grifolan of natural origin and astragaloside composition.
Background technology
At present, about 1.5 hundred million people in the whole world suffer from diabetes, and its incidence of disease just is being ascendant trend year by year.Hypoglycemic chemicals is taken for a long time has certain toxic and side effect.With modern study means exploitation natural products, exploitation active ingredient comes from the health food of food and integration of drinking and medicinal herbs Chinese medicine, but the assistant chemical medicine uses the minimizing drug dose, reduces toxic and side effect; Take separately and be applicable to the patient with slight symptoms, can take for a long time; To reducing diabetic's blood sugar level, improve patient's symptom, the reduction of patient misery has important social value.
Grifola frondosus (
Grifola frondosa) belong to a kind of macro fungi in Basidiomycotina, Hymenomycetes, Holobasidiomycetidae, Aphyllophorales, the Polyporus on the taxology, be the rare edible mushroom of a kind of medicine, food dual-purpose.Grifolan has antitumor significantly, hypoglycemic, anti-hepatitis, anti HIV-1 virus, stabilizing blood pressure, improves fat metabolism and improves effects such as function of immune system.Therefore be developed to plurality kinds of health care food at present,, become important ancillary drug in cancer patient's chemicotherapy process mainly as BRM.Astragaloside is the main active ingredient in the integration of drinking and medicinal herbs Chinese herbal medicine astragalus, have delay senility, anti-oxidant, protect the liver, various active such as antitumor.The bibliographical information astragaloside has the activity that suppresses alpha-glucosidase, significantly reduces the effect of alloxan mouse blood sugar level.Grifolan and astragaloside combination can obviously improve hypoglycemic separately effect, have the collaborative advantage that strengthens pharmacologically active.Do not see that grifolan and astragaloside compatibility are used for the report of hypoglycemic purposes.
Summary of the invention
For auxiliary improvement diabetic's symptom, the auxiliary patient's blood sugar level that reduces, the present invention provides a kind of hypoglycemic combination food.
The present invention mixes grifolan powder (active component) and astragaloside powder (active component) by mass ratio 1～2:2～1, obtain hypoglycemic combination food.Best mass ratio is 1:1.Grifolan content in the grifolan powder is greater than 50%; Astragaloside content in the astragaloside powder is greater than 50%.This combination food can become oral formulations by known processes, like granule, tablet, capsule, soft capsule etc.
Be rich in multiple nutrients compositions such as amino acid, polysaccharide and trace element in the Grifola Frondosa sporophore, grifolan wherein is main biological activity.Contain saponin(e, polysaccharide, flavones, amino acid, phenols and trace element etc. in the Radix Astragali, wherein saponin(e and polysaccharide are main active.
Pharmacological testing shows that grifolan of the present invention (GFP) and astragaloside (AST) combination food have the effect that reduces zoic model with hyperglycemia blood sugar, can work in coordination with the enhancing physiologically active, improve hypoglycemic separately function better; Toxicological test shows, combination food applications safety of the present invention.Therefore, combination food of the present invention can be used for preparing the health food and the medicine of auxiliary hyperglycemic, can improve the clinical symptoms due to diabetic's hyperglycaemia.
Concrete animal experiment situation is following:
Experiment one: to the therapeutic action (acute treatment test) of genotype diabetes B KKay mouse model
40 of KKay mouse, weight range are divided into 4 groups at random at 40 ± 2g: KKay model, GFP (40mgkg
-1), AST (40mg), GFP+AST (20+20 mgkg
-1) group, 10 every group, male and female half and half.Once irritate stomach (ig) administration.4h, 8h, 12h, 24h measure blood glucose value respectively before administration, after the administration, observe the administration change of blood sugar on the same day.Result of the test is seen table 1.The result shows, after the administration 4,8,12h blood sugar obviously descends, and is the most obvious with 8h hypoglycemic activity after the administration, it is about 30% that blood sugar descends, and blood sugar level rises gradually subsequently, and 24h returns to level before the administration after the administration.Both make up GFP+AST and obviously are superior to single usefulness, have synergy.
Different time is to the influence of KKay mouse blood sugar (mmol/L) behind table 1 single administration
N=10. x ± s. compares with self 0h,
*P<0.05,
*P<0.01; Compare with model group,
#P<0.05,
##P<0.01.
Experiment two: to the therapeutic action (chronic treatment test) of genotype diabetes B KKay mouse model
40 of KKay mouse, weight range are divided into 4 groups at random at 40 ± 2g: model group, GFP (40mgkg
-1D
-1), AST (40mgkg
-1D
-1), GFP+AST (20+20 mgkg
-1D
-1), 10 every group, male and female half and half; Other gets 10 C
57Mouse is that the normal control group is (because of C
57Genetic background mouse for KKay).Ig administration every day, every day 2 times, normal and model control group ig isometric(al) CMC-Na, 2 weeks of successive administration.After preceding 1 day of administration, administration 4,8,14 days, the tail point was got blood behind the mouse fasting 4h, measures blood glucose value with blood glucose meter.Result of the test is seen table 2.The result shows, in administration KKay mouse fasting blood-glucose is obviously descended, and explains that the present invention has the effect that reduces diabetes B KKay mouse fasting blood-glucose.Both make up GFP+AST and obviously are superior to single usefulness, have synergy.
Different time is to the hypoglycemic activity of KKay diabetic mice behind table 2 multiple dosing
N=10, x ± s. compares with model group,
*P<0.05,
*P<0.01.
Experiment three: to the effect of auxotype diabetes B mouse model
C
57The BL/6J mouse, in 3 ages in week, is divided into 5 groups: normal group, model group, GFP (40mgkg at random by 50
-1D
-1), AST (40mgkg
-1D
-1), GFP+AST (20+20 mgkg
-1D
-1), 10 every group, male and female half and half.Except that the normal control group, all the other each groups are fed high glucose and high fat feed (10% lard, 10% sucrose, 10% fresh hen egg, 70% basal feed).After 3 weeks, and lumbar injection (ip) Streptozotocin (STZ, with the citrate buffer solution preparation, 0.05M, pH4.5) 100mg/kg feeds 5 weeks of high glucose and high fat feed again.Ig administration every day, normal and model control group ig isometric(al) CMC-Na, 8 weeks of successive administration.In 1,2,3,4,5 weeks behind preceding 1 day of ip STZ, ip STZ, the tail point is got blood behind the mouse fasting 4h, measures blood glucose value with blood glucose meter.Result of the test is seen table 3.The result shows that the 1st week beginning fasting blood-glucose obviously descended after administration can make ip in mice STZ; Explain that the present invention has the effect that reduces auxotype diabetes B model mice fasting blood-glucose.Both make up GFP+AST and obviously are superior to single usefulness, have synergy.
The influence of table 3 pair auxotype diabetes B mouse fasting blood-glucose (mmol/L)
N=10, x ± s. compares with model group,
*P<0.05,
*P<0.01.
The present invention shows through The acute toxicity tests, and it is 19.6g/kg that mouse stomach is given GFP+AST one day maximum dosage-feeding (MTD), is equivalent to 120 times of effective doses.Product safety of the present invention is described, almost non-toxic side reaction.
The specific embodiment
Below in conjunction with embodiment the present invention is done to describe further.
Embodiment 1:
A kind of hypoglycemic combination food is mixed by mass ratio 1:1 by grifolan powder and astragaloside powder to be formed.
The preparation technology of grifolan powder is following: with the Grifola Frondosa sporophore grind into powder, 95% ethanolic solution that adds about 3 times of volumes stirs degreasing, during dimension 2 hours, suction filtration, sediment.Accurately take by weighing a certain amount of sediment, add the distilled water of solid-liquid ratio 1:10 (g/ml), 120 ℃ of following high pressure extraction 30 minutes.Centrifugal, get supernatant, added 1:1 volume absolute ethyl alcohol deposition 12 hours.Centrifugal, get deposition, in 60 ℃ of vacuum drying, weigh, get the grifolan powder, and measure the content (mg/g) of grifolan.These article proterties is: light brown powder, and odorless, tasteless, hygroscopicity is arranged, be slightly soluble in water, be insoluble to ethanol, the acetone and other organic solvent of high concentration.
Grifolan assay: adopt anthrone-sulfuric acid process to measure.The drawing standard curve is at 20～90 μ gml
-1Scope internal absorbance value and beta-dextran content are good linear relationship, and the calibration curve equation is Y=0.0085X-0.0424 (R=0.9990).Extracting sample solution 0.5ml, moisturizing is cooled off in ice-water bath to 1ml.Add anthrone sulphate reagent 4ml, shake up.Boil 10min in the boiling water bath.Cool off 10min in the ice-water bath again.With distilled water is blank, and the 620nm place measures absorbance.Grifolan content is 586.95mg/g in the grifolan powder.
The preparation technology of grifolan powder and content assaying method are public method.
The preparation technology of astragaloside powder is following: Milkvetch Root, cut the thick medicine materical crude slice of about 0.5cm, and add 70% alcohol reflux and extract 2 times, add 10 times of amounts for the first time, extract 90min; Add 8 times of amounts the 2nd time, extract 60min, merge 70% ethanol extract, filter, filtrate decompression concentrates steams ethanol to the greatest extent; Low-grade fever adds water to 2000ml, places 12h, filters, and filtrating is with an amount of D101 macroporous absorbent resin; The filtrating of adsorbing discards, and continues the D101 macroporous absorbent resin after the water flushing absorption, can't check reduced sugar to washing lotion till, discard water lotion, use an amount of 30% alcohol flushing again; Discard 30% pure washing lotion, use 70% ethanol elution again, can't check Astragaloside IV to eluent till, decompression concentrates 70% ethanol eluate; And in 60 ℃ of vacuum drying, weigh, get the astragaloside powder, and measure the content (mg/g) of astragaloside.These article proterties is: chocolate brown powder, and odorless, mildly bitter flavor has hygroscopicity, is dissolved in alcohol and water.
The astragaloside assay: adopt AAS: the mensuration wavelength is 560nm, and developer is selected vanillic aldehyde-perchloric acid color development system for use, is reference substance with the Astragaloside IV, and is good in 50-250 μ g scope internal linear relation.These article of getting 10mg, the accurate title, decide, and adds water 10ml, and heating makes dissolving; Extract three times with water-saturated n-butanol, each 20ml merges n-butanol liquid, reclaims n-butanol to doing with Rotary Evaporators; Residue adds methyl alcohol gradation dissolving, quantitatively is transferred in the 10ml measuring bottle, adds methyl alcohol to scale, shakes up.The accurate 0.20ml that draws puts in the tool plug test tube, in water-bath, volatilizes solvent, each accurate 5% vanillic aldehyde glacial acetic acid solution 0.2ml and perchloric acid 0.8ml of adding; Close plug shakes up, and heating is 20 minutes in 70 ℃ of water-baths; Cool off with flowing water immediately after the taking-up; Add glacial acetic acid solution 5.0ml, shake up, measure trap in the 560nm wavelength.Read the amount that is equivalent to Astragaloside IV the need testing solution from calibration curve, try to achieve astragaloside content.Astragaloside content is 577.31mg/g in the astragaloside powder.
The preparation technology of astragaloside powder and content assaying method are public method.
The preparation of granule: preparation technology prepares granule by granule.Every bag contains grifolan+astragaloside is 60mg+60mg.
Embodiment 2:
A kind of hypoglycemic combination food evenly is made up of grifolan powder and astragaloside powder mixes, and both proportionings are 1:2.
The grifolan powder is purchased the grand hundred million agricultural development Co., Ltds in the Qingyuan County, Zhejiang.
The astragaloside powder is purchased the Ze Lang agricultural science and technology Co., Ltd in Nanjing.
The preparation of tablet prepares tablet by tablet producing technology.Every contains grifolan+astragaloside is 20mg+40mg.
Other is with embodiment 1.
Embodiment 3:
A kind of hypoglycemic combination food is mixed by grifolan powder and the astragaloside powder proportioning by 2:1.
The grifolan powder is purchased the grand hundred million agricultural development Co., Ltds in the Qingyuan County, Zhejiang.
The astragaloside powder is purchased the Ze Lang agricultural science and technology Co., Ltd in Nanjing.
The preparation of capsule prepares capsule by capsules preparation technique.Every contains grifolan+astragaloside is 40mg+20mg.
Other is with embodiment 1.
Embodiment 4:
Preparation of soft capsule is by soft capsule preparation prepared soft capsule.Every contains grifolan+astragaloside is 30mg+30mg.
Other is with embodiment 1.
Every day, oral dose was 240mg in active component composition grifolan+astragaloside.Be used for auxiliary hyperglycemic, the granule instructions of taking is every day 2 times, each 1 bag, and warm boiled water; The tablets method is every day 2 times, each 2; Capsule and soft capsule instructions of taking are every day 2 times, each 2.3 months is a course of treatment.
Claims (3)
1. a hypoglycemic combination food is characterized in that: mixed by mass ratio 1:2～2:1 by grifolan powder and astragaloside powder and form;
Said grifolan powder is by extracting in the Grifola Frondosa sporophore, and wherein grifolan content is greater than 50%;
Said astragaloside powder is by extracting in the Radix Astragali, and wherein astragaloside content is greater than 50%.
2. a kind of hypoglycemic combination food according to claim 1 is characterized in that: mixed by mass ratio 1:1 by grifolan powder and astragaloside powder and form.
3. a kind of hypoglycemic combination food according to claim 1 is characterized in that: mixed by mass ratio 1:2～2:1 by grifolan powder and astragaloside powder and process granule or tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102844487A CN102356837B (en) | 2011-09-23 | 2011-09-23 | Combined food for reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102844487A CN102356837B (en) | 2011-09-23 | 2011-09-23 | Combined food for reducing blood sugar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102356837A CN102356837A (en) | 2012-02-22 |
| CN102356837B true CN102356837B (en) | 2012-11-07 |
Family
ID=45582262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102844487A Expired - Fee Related CN102356837B (en) | 2011-09-23 | 2011-09-23 | Combined food for reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102356837B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489459A (en) * | 2014-12-04 | 2015-04-08 | 黄艳红 | Qianfo-milkvetch root polysaccharide and preparation process thereof |
| CN106109554A (en) * | 2016-08-08 | 2016-11-16 | 南京财经大学 | A kind of compositions improving insulin resistant |
| CN106912949A (en) * | 2017-03-15 | 2017-07-04 | 福建农林大学 | A kind of grifola frondosus spirulina complex preparation health food and preparation method thereof |
| CN115039882B (en) * | 2022-06-27 | 2024-01-26 | 华中农业大学 | Polysaccharide composition for reducing postprandial blood sugar and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259160A (en) * | 2008-04-18 | 2008-09-10 | 天津生机集团股份有限公司 | Compound preparations for treating birdsvirosis and preparation thereof |
| CN101385909A (en) * | 2008-09-12 | 2009-03-18 | 天津科技大学 | Extraction method of natural soluble polysaccharide using radial chromatography |
-
2011
- 2011-09-23 CN CN2011102844487A patent/CN102356837B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259160A (en) * | 2008-04-18 | 2008-09-10 | 天津生机集团股份有限公司 | Compound preparations for treating birdsvirosis and preparation thereof |
| CN101385909A (en) * | 2008-09-12 | 2009-03-18 | 天津科技大学 | Extraction method of natural soluble polysaccharide using radial chromatography |
Non-Patent Citations (2)
| Title |
|---|
| 灰树花子实体多糖的降血糖活性和对α-葡萄糖苷酶活性的影响;雷红 等;《食品科学》;20100601;第31卷(第11期);第263-267页 * |
| 雷红 等.灰树花子实体多糖的降血糖活性和对α-葡萄糖苷酶活性的影响.《食品科学》.2010,第31卷(第11期),第263-267页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102356837A (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harizal et al. | Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in rodent | |
| CN102356837B (en) | Combined food for reducing blood sugar | |
| CN101396445A (en) | Use of Chinese goldthread total alkali in preparing medicine for treating diabetes complication | |
| CN101371902A (en) | Effect of natural active glycogen for reducing blood sugar and blood fat | |
| CN102641317A (en) | Golden wave extract and application thereof in preparation of antidiabetic agent | |
| CN114224978B (en) | Traditional Chinese medicine compound composition with anti-fatigue function and application thereof | |
| CN102356872B (en) | Blood lipid-lowering composite food | |
| CN101843884B (en) | Method for testing quality of antiviral oral liquid for treating hand-foot-and-mouth disease | |
| CN102697781B (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN104666585A (en) | Application of radix rehmanniae leaf extract in preparation of blood glucose-reducing medicines | |
| KR101537856B1 (en) | A pharmaceutical composition for preventing and treating nonalcoholic fatty liver disease comprising extraction fraction with enhanced gincenoside rb1 from panax ginseng as an active ingredient | |
| CN101423558B (en) | Eupatorium adenophorum spreng polysaccharide and preparation method and use | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN106109554A (en) | A kind of compositions improving insulin resistant | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN101912114B (en) | Composition for improving memory | |
| CN104000862A (en) | Application of total flavonoids of herba epimedii in preparing medicine for preventing hepatic fibrosis | |
| KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| CN101474346A (en) | Longstamen onion bulb extract as well as preparation method and application thereof | |
| CN107913277A (en) | The purposes of the anti-uric acid nephropathy of tanshinone | |
| CN101011543B (en) | Antineoplastic medicine composition | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN100532395C (en) | Alpha-glucosan originated from Grifola frondosa sporophore and its preparation process and use | |
| CN103860877B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121107 Termination date: 20150923 |
|
| EXPY | Termination of patent right or utility model |